Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial-Reference-Cited by-全球学者库

Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial

Published:2016-08 Issue:8 Volume:3 Page:e343-e350
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Bunupuradah Torsak,Kiertiburanakul Sasisopin,Avihingsanon Anchalee,Chetchotisakd Ploenchan,Techapornroong Malee,Leerattanapetch Niramon,Kantipong Pacharee,Bowonwatanuwong Chureeratana,Banchongkit Sukit,Klinbuayaem Virat,Mekviwattanawong Sripetcharat,Nimitvilai Sireethorn,Jirajariyavej Supunnee,Prasithsirikul Wisit,Munsakul Warangkana,Bhakeecheep Sorakij,Chaivooth Suchada,Phanuphak Praphan,Cooper David A,Apornpong Tanakorn,Kerr Stephen J,Emery Sean,Ruxrungtham Kiat

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference21 articles.

1. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach,2013

2. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study;Molina;J Acquir Immun Defic Syndr,2010

3. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial;Soriano;J Antimicrob Chemother,2008

4. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study;Mallolas;J Acquir Immun Defic Syndr,2009

5. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampin;Avihingsanon;Antivir Ther,2008

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperbilirubinemia during Atazanavir/Ritonavir Treatment in HIV-infected Patients at Vajira Hospital, a Tertiary Hospital in Thailand;2023-06-26

2. Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance;Journal of Antimicrobial Chemotherapy;2023-04-27

3. Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis;Drug Metabolism and Pharmacokinetics;2022-12

4. Adolescent mental health during covid-19 pandemics: a systematic review;International Journal of Adolescent Medicine and Health;2022-11-02

5. Higher prevalence of QTc interval prolongation among virologically suppressed older people with HIV;AIDS;2022-08-12